Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech Euroopa Liit - eesti - EMA (European Medicines Agency)

human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech

xbiotech germany gmbh - inimese iggl monoklonaalne antikeha, mis on spetsiifiline inimese interleukiin-1 alfa suhtes - kolorektaalne kasvaja - antineoplastilised ained - ravi metastaatilise kolorektaalse vähi.

Comirnaty Euroopa Liit - eesti - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Oxyglobin Euroopa Liit - eesti - EMA (European Medicines Agency)

oxyglobin

opk biotech netherlands bv - hemoglobiin glutameer-200 (veis) - vere asendajad ja perfusioonilahused - koerad - oxyglobin pakub hapniku veavad toetada koerte parandada kliinilisi nähte, aneemia vähemalt 24 tundi, sõltumatu haigust.

Removab Euroopa Liit - eesti - EMA (European Medicines Agency)

removab

neovii biotech gmbh - catumaxomab - ascites; cancer - muud antineoplastilised ained - removab on näidustatud pahaloomulise astsiidi intraperitoneaalseks raviks epcam-positiivsete kartsinoomidega patsientidel, kellel ei ole standardseid ravimeid või pole enam võimalik.

POLTECH MDP radiofarmatseutiline komplekt Eesti - eesti - Ravimiamet

poltech mdp radiofarmatseutiline komplekt

institute of atomic energy polatom - tehneetsium(99mtc)medronaat - radiofarmatseutiline komplekt - 5mg 6tk

POLTECHMBRIDA radiofarmatseutiline komplekt Eesti - eesti - Ravimiamet

poltechmbrida radiofarmatseutiline komplekt

institute of atomic energy polatom - tehneetsium(99mtc)mebrofeniin - radiofarmatseutiline komplekt - 20mg 6tk

POLTECHMBRIDA radiofarmatseutiline komplekt Eesti - eesti - Ravimiamet

poltechmbrida radiofarmatseutiline komplekt

narodowe centrum badan jadrowych - tehneetsium(99mtc)mebrofeniin - radiofarmatseutiline komplekt - 20mg 6tk

POLTECHNET radionukliidgeneraator Eesti - eesti - Ravimiamet

poltechnet radionukliidgeneraator

narodowe centrum badan jadrowych - tehneetsium(99m tc)pertehnetaat - radionukliidgeneraator - 1tk

POLTECHRBC süstelahuse lüofilisaat Eesti - eesti - Ravimiamet

poltechrbc süstelahuse lüofilisaat

institute of atomic energy polatom - naatriumpürofosfaat dekahüdraat+tinakloriiddihüdraat - süstelahuse lüofilisaat - 13,4mg+4,3mg 6tk

ATryn Euroopa Liit - eesti - EMA (European Medicines Agency)

atryn

laboratoire francais du fractionnement et des biotechnologies - antithrombin alfa - antitrombiini iii defitsiit - antitrombootilised ained - atryn on näidustatud veenide trombemboolia profülaktikaks kaasasündinud antitrombiini puudulikkusega patsientide kirurgias. atryni manustatakse tavaliselt koos hepariini või madala molekulmassiga hepariiniga.